SNOA.US
SNOA.US

Last Day

Drug Manufacturers – Specialty & Generic

Latest Valuation

  • Trailing PE:
  • Forward PE:
  • Price Sales TTM:
  • Price Book MRQ:
  • Enterprise Value:
  • Enterprise Value Revenue:
  • Enterprise Value Ebitda:
  • Beta:

Key Highlights

  • Shares Outstanding:
  • Market Capitalization:
  • Market Capitalization Mln:
  • EBITDA:
  • PE Ratio:
  • PEG Ratio:
  • Wall Street Target Price:
  • Book Value:
  • Dividend Share:
  • Dividend Yield:
  • Earnings Share:
  • EPS Estimate Current Year:
  • EPS Estimate Next Year:
  • EPS Estimate Next Quarter:
  • EPS Estimate Current Quarter:
  • Most Recent Quarter:
  • Profit Margin:
  • Operating Margin TTM:
  • Return On Assets TTM:
  • Return On Equity TTM:
  • Revenue TTM:
  • Revenue Per Share TTM:
  • Quarterly Revenue Growth YOY:
  • Gross Profit TTM:
  • Diluted Eps TTM:
  • Quarterly Earnings Growth YOY:

Basic Information

  • Type:
  • Name:
  • Exchange:
  • Currency Code:
  • Currency Name:
  • Currency Symbol:
  • Country Name:
  • Fiscal Year End:
  • IPO Date:
  • International Domestic:
  • Sector:
  • Industry:
  • Address:
  • Country:
  • Listings:
  • Web URL:
  • Full Time Employees:
  • Updated At:
  • Gic Sector:
  • Gic Group:
  • Gic Industry:
  • Gic SubIndustry:

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for use in emergencies and on mucous membranes, cuts, abrasions, burns, and body surfaces; and Endocyn root canal irrigation solutions. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado. Address: 5445 Conestoga Court, Boulder, CO, United States, 80301

2024-6-30